Interleukin-4 receptor-targeted liposomal doxorubicin as a model for enhancing cellular uptake and antitumor efficacy in murine colorectal cancer

Yang, Chih‐Yung; Liu, Hong‐Wen; Tsai, Ya-Ching; Tseng, Ju-Yu; Liang, Shu-Ching; Chen, Chin-Yau; Lian, Wei-Nan; Wei, Ming-Cheng; Lu, Maggie; Lu, Ruey-Hwa; Lin, Chi‐Hung; Jiang, Jeng‐Kai

doi:10.1080/15384047.2015.1095397

Cited by 18 publications

(11 citation statements)

References 53 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…and Chi et al. conjugated AP1 to liposomes for delivering doxorubicin to murine colorectal cancer IL‐4 receptor positive cells (CT26‐IL4R) and human squamous non‐small cell lung cancer (H226), respectively 79b,82. In these in vivo studies, tumor uptake of liposomes was enhanced with the use of the peptide specific ligand to IL‐4R (Figure C) and tumor volume was significantly decreased in IL‐4R peptide conjugated liposomes as compared to unconjugated liposomes 79b,82…”

Section: Common Tumor Targets For Receptor‐mediated Drug Deliverymentioning

confidence: 98%

“…The IL‐4 receptor is known to be overexpressed in glioblastomas, pancreatic, ovarian, lung, renal, breast, and colorectal cancers . IL‐4 causes the direct inhibition of cancer in vitro .…”

Section: Common Tumor Targets For Receptor‐mediated Drug Deliverymentioning

confidence: 99%

“…Here, the combination of IL‐4 receptor targeting and pH‐mediated drug release resulted in a 40.4% or 13.4% reduction of breast cancer tumor (MDA‐MB‐231 xenograft) weight compared to treatment with free drug or non‐targeted micelles, respectively 81a. The AP peptide could also be used to target IL‐4 receptors overexpressed on glioma, colorectal cancer, or lung cancer cells 79b. Consequently, Yang et al.…”

Section: Common Tumor Targets For Receptor‐mediated Drug Deliverymentioning

confidence: 99%

See 2 more Smart Citations

Advances in Receptor‐Mediated, Tumor‐Targeted Drug Delivery

Large

Soucy

Hebert

et al. 2018

Advanced Therapeutics

129

101

View full text Add to dashboard Cite

Receptor-mediated drug delivery presents an opportunity to enhance therapeutic efficiency by accumulating drug within the tissue of interest and reducing undesired, off-target effects. In cancer, receptor overexpression is a platform for binding and inhibiting pathways that shape biodistribution, toxicity, cell binding and uptake, and therapeutic function. This review will identify tumor-targeted drug delivery vehicles and receptors that show promise for clinical translation based on quantitative in vitro and in vivo data. The authors describe the rationale to engineer a targeted drug delivery vehicle based on the ligand, chemical conjugation method, and type of drug delivery vehicle. Recent advances in multivalent targeting and ligand organization on tumor accumulation are discussed. Revolutionizing receptor-mediated drug delivery may be leveraged in the therapeutic delivery of chemotherapy, gene editing tools, and epigenetic drugs.in the site of interest. This is clinically important as reaching a therapeutic dosage locally and reducing systemic toxicity can be life-threatening or life-saving events for cancer patients.The design of targeted DDVs can be optimized by altering the size, shape, material, ligand, and ligand orientation. For systemic delivery, spherical DDVs less than 200 nm in diameter are standard, which is balanced by the trade off between surface area and volume ratio. DDVs are prepared from biomaterials based on the size, hydrophobicity, and ideal release of the drug. There are a diverse range of ligand candidates for DDV functionalization, including monoclonal antibodies (mAbs), peptides, oligosaccharides, small molecules, and aptamers. [5] These ligands can be tethered to vehicles or conjugated directly to drugs by covalent (typically thiol or amide-based reactions, or "click" chemistry) or noncovalent attachment; the type of reaction is often based on the material of the DDV. [6] Multi-targeted and patterned DDVs improved cancer cell binding and the overall therapeutic benefit in vivo. The ideal DDV platform may be rationally designed by evaluating the drug, release mechanism, mode of delivery into the body, and target cells.Utilizing these approaches, targeted DDVs were successfully translated from the research setting into clinical use, or are currently in preclinical trials. [7] Liposomal based DDVs were approved for use in cancer therapy, treating fungal diseases, analgesics, photodynamic therapy, and viral vaccines. [8] Specifically, FDA approved liposomal drug formulations, such as Mepact, Maribo, and Epaxal were proven to be effective for the treatment of nonmetastatic osteosarcoma, acute lymphoblastic leukemia, and hepatitis A, respectively. [9] Many targeted DDVs in clinical use are utilized for the treatment of multiple cancer types, as there is often broad overlap in malignant receptor overexpression across various carcinogenic tissues (Figure 1). The widely successful drug Pembrolizumab (Keytruda), a humanized IgG4 isotype mAb that targets the programmed cell death (PD-1) rec...

show abstract

Section: Common Tumor Targets For Receptor‐mediated Drug Deliverymentioning

confidence: 98%

Section: Common Tumor Targets For Receptor‐mediated Drug Deliverymentioning

confidence: 99%

Section: Common Tumor Targets For Receptor‐mediated Drug Deliverymentioning

confidence: 99%

See 1 more Smart Citation

Advances in Receptor‐Mediated, Tumor‐Targeted Drug Delivery

Large

Soucy

Hebert

et al. 2018

Advanced Therapeutics

129

101

View full text Add to dashboard Cite

show abstract

“…The antitumor effect of doxorubicin has been widely reported (61). In a previous study, the liposomal form of doxorubicin was conjugated with a ligand of the atherosclerotic plaque-specific peptide-1 (AP1), a peptide characterized by its ability to bind IL-4R; Yang et al (62) proposed that AP1-conjugated liposomal doxorubicin exhibits an increased and selective cytotoxic effect on CRC cells, and has potential as a targeted anticancer therapy. Collectively, the aforementioned studies demonstrated that the inhibition of IL-4, IL-4R, IL-13Rα1 and IL-13Rα2 may be beneficial for colon cancer.…”

Section: Targeting Il-4 Il-13 Il-4r and Il-13rα2 In Colon Cancer Thmentioning

confidence: 99%

Signal transducer and activator of transcription 6 as a target in colon cancer therapy (Review)

et al. 2020

View full text Add to dashboard Cite

Signal transducer and activator of transcription 6 (STAT6) is a member of the STAT family of proteins that serve key roles in the initiation of tumorigenesis and malignant transformation. STAT6 is highly expressed in several types of cancer, including breast, pancreatic, prostate and colorectal cancer. STAT6 transduces signals in response to the binding of interleukin (IL)-4 and IL-13 to their receptors and regulates the expression of genes involved in the immune response, cell survival, tumor proliferation and metastasis. Patients with colorectal cancer exhibit high STAT6 activity in the colonic epithelium, and STAT6 expression is associated with lower survival rates, lymph node metastasis, changes in the epithelial barrier function and alterations in the inflammatory response. A number of studies investigating experimental models and cancer cell lines have revealed that STAT6 is associated with tumor growth and development, as well as with increased invasion and metastasis, suggesting that STAT6 inhibition may serve as a novel therapeutic strategy in colon cancer. The present review summarizes the evidence with regard to the implications of STAT6 in cancer biology and the direct and indirect effects on colon tumor transformation. Furthermore, the current treatment strategies targeting the IL-4/IL-13/STAT6 axis in colon cancer are discussed.

show abstract

“…This configuration of monolayer lipids is outside of the scope of this paper and reviews on this subject can be found elsewhere [30]. It should be noted, however, that many similar applications involving liposomes, such as tumor drug delivery and gene therapy, and targeted imaging are being pursued in this field [31,32,33,34,35,36].…”

Section: Ultrasoundmentioning

confidence: 99%

Spatially Specific Liposomal Cancer Therapy Triggered by Clinical External Sources of Energy

et al. 2019

View full text Add to dashboard Cite

This review explores the use of energy sources, including ultrasound, magnetic fields, and external beam radiation, to trigger the delivery of drugs from liposomes in a tumor in a spatially-specific manner. Each section explores the mechanism(s) of drug release that can be achieved using liposomes in conjunction with the external trigger. Subsequently, the treatment’s formulation factors are discussed, highlighting the parameters of both the therapy and the medical device. Additionally, the pre-clinical and clinical trials of each triggered release method are explored. Lastly, the advantages and disadvantages, as well as the feasibility and future outlook of each triggered release method, are discussed.

show abstract

Interleukin-4 receptor-targeted liposomal doxorubicin as a model for enhancing cellular uptake and antitumor efficacy in murine colorectal cancer

Cited by 18 publications

References 53 publications

Advances in Receptor‐Mediated, Tumor‐Targeted Drug Delivery

Advances in Receptor‐Mediated, Tumor‐Targeted Drug Delivery

Signal transducer and activator of transcription 6 as a target in colon cancer therapy (Review)

Spatially Specific Liposomal Cancer Therapy Triggered by Clinical External Sources of Energy

Contact Info

Product

Resources

About